- Cough, Mucus, and Respiratory Health: A Complete Guide - August 18, 2025
- Flogoprofen: what it's used for and how to take it - June 21, 2025
- What is Movicol oral solution in sachet used for and how to take it? - June 18, 2025
A team of scientists from Cambridge has created a revolutionary new test to detect prostate cancer. This test, developed by EDX Medical Group, promises to transform the way this disease is diagnosed and treated. Its high accuracy and ability to detect cancer in early stages are some of the highlights.
High precision thanks to the combination of biomarkers
The new test uses more than 100 clinically validated biomarkers that are analyzed in blood and urine samples. These biomarkers can identify the presence or absence of cancer cells, detect signs of cancer in its early or advanced stages, and classify the type of cancer according to its aggressiveness.
Biomarker analysis is performed using a proprietary artificial intelligence (AI) algorithm. This algorithm highlights the early signs of cancer, helping doctors select the most appropriate treatment for each patient.
According to EDX Medical scientists, The test has sensitivity and specificity levels that vary between 96 % and 99 %. These percentages are significantly higher than traditional tests such as prostate-specific antigen (PSA) or biopsies.The latter have an accuracy of less than 50 %, making the new test a crucial advance in the diagnosis of this disease.
Benefits for patients and health professionals
The new noninvasive “super test” could significantly reduce the need for invasive procedures such as digital rectal exams (DREs) and unnecessary MRIs. It also offers a multi-omic analysis that includes genetic, epigenetic, proteomic and transcriptomic information, giving a more detailed view of the status of prostate cancer.
The test also has a special focus on patients from ethnic minorities, who are at higher risk of developing prostate cancer. Experts say the ability to detect aggressive cancer subtypes in these populations could save lives.
Sir Chris Evans, Founder and Chief Scientific Officer of EDX Medical, said the test represents a major advance in the detection and treatment of prostate cancer. “What sets this test apart is the use of so many biomarkers and the best technology available,” he commented.
A promising future for the fight against prostate cancer
The EDX Medical team hopes to secure regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) in the coming months. The test is expected to be available later this year or in early 2026.
This breakthrough could mark a significant change in the early detection and treatment of prostate cancer, improving options for patients and reducing overall medical costs.
